Work

Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

Year: 2017

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(17)30561-0

Authors: D.S. Hong, A. Dowlati, H.A. Burris, J.J. Lee, M.S. Brose, A.F. Farago, T.M. Bauer, M. Taylor, A.T. Shaw, S. Smith, N. Nanda, S. Cruikshank, M.C. Cox, R.C. Doebele

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2587040951

FWCI: 1.821

Cites:

Cited by: 10

Related to: 10